Smruthi Organics is discontinuing its Finished Dosage Formulations (FDF) division to concentrate on its core Active Pharmaceutical Ingredient (API) and Contract Research and Manufacturing Services (CRAMS) businesses. The company reported a 19.08% revenue decline but improved EBITDA margins.
Smruthi Organics Divests FDF Unit for API and CRAMS Focus
For FY 2025-2026, Smruthi Organics Ltd. reported Revenue from Operations of ₹101.97 crore and EBITDA of ₹13.16 crore.
Reader Takeaway: Divestment of FDF aids margin expansion; ANVISA inspection is a key watch point.
What just happened
Smruthi Organics Ltd. has decided to strategically discontinue its Finished Dosage Formulations (FDF) division. This move aims to channel resources and capital exclusively into its core Active Pharmaceutical Ingredient (API) business and its growing Contract Research and Manufacturing Services (CRAMS) segment.
Why this matters
The company reported a 19.08% year-on-year decline in revenue for FY 2025-2026, reaching ₹101.97 crore. However, profitability showed resilience, with EBITDA increasing by 7.25% to ₹13.16 crore, and EBITDA margins expanding to 12.89% from 9.74% in the previous year. This margin expansion is attributed to improved operational focus and cost control.
A one-time exceptional charge of ₹0.46 crore related to new Labour Codes impacted the net profit, which saw a marginal decline to ₹3.43 crore from ₹3.56 crore.
The Board of Directors has recommended a dividend of ₹1.50 per share (15%).
The backstory
Smruthi Organics has been navigating a challenging revenue environment, with the decline attributed to lower volumes in certain categories and a deliberate avoidance of low-margin business. The strategic decision to exit the FDF division is part of a broader plan to streamline operations and enhance focus on higher-margin business areas.
What changes now
With the FDF division winding down, the company will dedicate its efforts to scaling up its API and CRAMS segments. The CRAMS business is anticipated to become a significant driver of future revenue and profit growth. Additionally, securing EDQM approval opens potential avenues for expansion into the European market.
Risks to watch
Pricing pressure from increasing competition, particularly from non-traditional players, poses a risk to volume and margin stability in the API segment.
Peer comparison
While specific peer data is not provided in the filing, the trend of Indian pharmaceutical companies focusing on niche, high-margin segments like APIs and CRAMS is a common industry strategy.
Context metrics (time-bound)
- Revenue from Operations (FY 2025-2026): ₹101.97 crore (down 19.08% YoY)
- EBITDA (FY 2025-2026): ₹13.16 crore (up 7.25% YoY)
- EBITDA Margin (FY 2025-2026): 12.89% (up from 9.74%)
- Net Profit (FY 2025-2026): ₹3.43 crore (down marginally)
- Dividend Recommendation: ₹1.50 per share
What to track next
Investors should monitor the successful execution of the FDF division's wind-down. Key regulatory events, such as the upcoming ANVISA inspection in Brazil, are critical for assessing market entry potential in South America. The growth and performance of the CRAMS segment will also be crucial indicators for future expansion.